Alphamab Doses First Patient in Phase II Trial of JSKN033 for Advanced Cervical Cancer

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Alphamab Oncology ( (HK:9966) ) has issued an update. Alphamab Oncology has initiated a phase II clinical study in which the first patient has been dosed with JSKN033, a high-concentration subcutaneous co-formulation combining a HER2 bispecific ADC and a PD-L1 inhibitor, alongside platinum-based chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer. The trial targets a major unmet need in cervical cancer, where current immunotherapy plus platinum regimens deliver suboptimal responses for many patients despite being the standard of care. JSKN033 is designed to offer improved convenience via subcutaneous dosing and lower hematologic toxicity, enabling flexible combination with cisplatin or carboplatin and potentially enhancing safety for patients with differing renal function and tolerance levels. Early clinical data in previously treated cervical cancer patients have shown promising efficacy and manageable safety, supporting its advancement into first-line combination therapy and underpinning Alphamab’s broader strategy to build a competitive ADC and immunotherapy-franchise across multiple solid tumor indications. The JSKN033-202 study is an open-label, multicenter phase II trial evaluating safety, efficacy and PK/PD of JSKN033 with investigator-chosen platinum-based agents and optional bevacizumab in advanced cervical cancer. Alongside this program, Alphamab is running additional phase II monotherapy studies of JSKN033 in later-line cervical and endometrial cancers and HER2-mutant or expressing non-small cell lung cancer, reinforcing its position in the oncology biologics space and potentially expanding its addressable market if clinical outcomes are favorable. The most recent analyst rating on (HK:9966) stock is a Buy with a HK$9.60 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page. More about Alphamab Oncology Alphamab Oncology is a leading Chinese biopharmaceutical company focused on oncology, leveraging proprietary technology platforms in antibody-drug conjugates, bispecific antibodies and multifunctional protein engineering. Its in-house pipeline spans ADCs, monoclonal and bispecific antibodies, including one NMPA-approved product and multiple late-stage clinical candidates targeting global cancer markets. The company uses structure-guided molecular modeling and protein engineering to design next-generation multifunctional biologic drugs. With a fully integrated R&D platform and expertise in antibody-based therapies, Alphamab aims to address significant unmet medical needs in cancer treatment and expand its footprint in both domestic and international biopharma markets. Average Trading Volume: 1,573,200 Technical Sentiment Signal: Buy Current Market Cap: HK$9.77B For a thorough assessment of 9966 stock, go to TipRanks’ Stock Analysis page.